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distribution, discount rate and non performing transplant.
RESULTS: In the combined analysis, considering the expected
genotypic distribution for the Portuguese population, treatment
with PEGIFN+RIB was estimated to increase discounted life
expectancy by 1.61 years (23.30 vs 2169) and quality-adjusted
life expectancy by 1.17 QALYs compared to no treatment. Direct
costs were projected to be €29,410 with PEGIFN+RIB and
€33,788 with no treatment. These results corresponded to ICERs
of -€2.19 and -€3742 per life year gained and per QALY gained,
respectively. CONCLUSIONS: The use of of PEGIFN+RIB
(PEGASYS/COPEGUS) vs no treatment in patients with HIV/
HCV co-infection is a cost-saving (dominant) alternative in the
Portuguese setting for all genotypes.
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OBJECTIVES: To estimate the cost-effectiveness of caspofungin
versus amphotericin B, voriconazole, and anidulafungin in the
treatment of invasive candidiasis in a subgroup of patients who
are infected by ﬂuconazole-resistant Candida species and in
patients who cannot be treated with ﬂuconazole due to other
reasons. METHODS: For this analysis a lifetime Markov model
was used with following health states: success, failure, and death
over two treatment lines. A randomized clinical trial comparing
caspofungin and amphotericin B was used to estimate daily tran-
sition probabilities. The corresponding probabilities for vori-
conazole and anidulafungin were estimated based on indirect
comparisons using amphotericin B as the common comparator.
The analysis was conducted from a societal perspective. Direct
costs inside the health care system were included. Outcomes were
reported as cost per life-year gained. To determine the robustness
of the model and the impact of uncertainty, uni- and multivariate
sensitivity analyses were carried out. RESULTS: In the base case
analysis the 95% conﬁdence intervals of the incremental life
years were estimated at 0.23(-0.29, 0.85), 0.21(-0.31, 0.88),
and 0.11(-0.37, 0.71) compared to amphotericin B, voricona-
zole, and anidulafungin respectively. Corresponding intervals for
incremental costs were €1825(-€3954, €5581), €40(-€5243,
€3354), and -€415(-€4938, €2570). Cost per life year gained
was €7942 and €189 compared to amphotericin B and voricona-
zole. Caspofungin was dominant compared to anidulafungin.
Probabilistic sensitivity analyses showed that at a willingness to
pay threshold of €20,000/QALY, caspofungin has a 62%, 72%,
and 68% probability to be cost-effective relative to respectively
amphotericin B, voriconazole and anidulafungin. Univariate sen-
sitivity analyses showed that results were sensitive to changes in
efﬁcacy parameters and infection-related mortality. CONCLU-
SIONS: The present model suggests that caspofungin is cost-
effective in the treatment of invasive candidiasis in this speciﬁc
subgroup of patients. Potential limitation of the model is that
efﬁcacy and failure estimates are partly based on indirect
comparisons.
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OBJECTIVES: This study evaluated the cost-effectiveness of
peginterferon alfa-2b (1.5 mcg/kg/wk) plus 800–1400 mg/day
ribavirin (PEG2b 1.5/R) in patients with refractory chronic
hepatitis C (HCV) whose previous combination therapy with
pegylated or standard interferon alfa and ribavirin failed.
METHODS: A Markov model was developed based on an
open-label trial (EPIC) in which patients received PEG2b 1.5/R
or no further drug therapy. Patients with genotypes 1/4 (G1/4)
HCV with undetectable HCV RNA at week 12 were treated for
48 weeks; patients with detectable HCV RNA were discontin-
ued at 18 weeks. G2/3 HCV patients were treated for 24
weeks. Data on the natural history of disease, drug and medical
resource costs (2007 euros), and utility values were estimated
from published literature. Using a Spanish perspective, the
model estimated the incremental cost-effectiveness ratio (ICER)
for PEG2b 1.5/R vs. no further treatment based on cost per
quality-adjusted life year (QALY) gained over a patient’s life-
time. A second-order probabilistic Monte Carlo sensitivity
analysis was conducted to assess the effects of parameter uncer-
tainty (efﬁcacy) on the study ﬁndings. RESULTS: In G1 and G4
patients, PEG2b 1.5/R led to higher costs (€19,300 vs. €10,100)
and increased QALYs (10.62 vs. 10.15) compared with no drug
therapy (ICER: €19,600 per QALY gained). In G2/3 patients,
treatment costs were twice as high for the PEG2b 1.5/R
regimen compared with no therapy (€22,200 vs. €10,100); the
incremental gain in QALYs was greater than it was for the G1
and G4 groups (11.99 vs. 10.15) (ICER: €6,600 per QALY
gained). The probabilistic sensitivity analysis suggests a 99%
probability that the ICER for PEG2b 1.5/R among refractory
patients is at or below a €30,000 per QALY gained threshold
for both genotype groups. CONCLUSIONS: PEG2b 1.5/R is in
the range of the widely accepted cost-effectiveness threshold for
medical interventions in Spain.
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OBJECTIVES: To systematically review the evidence for long-
term effectiveness and cost-effectiveness of screening for hepatitis
C virus (HCV) infection. METHODS: We performed a system-
atic literature search (March 2007) on the long-term health and
economic effects of HCV screening. We included health technol-
ogy assessment (HTA) reports, systematic reviews, long-term
clinical trials, full health economic studies and decision-analytic
modelling studies assessing the impact of HCV screening with a
sufﬁciently long time horizon and a patient-relevant long-term
outcome such as life-years gained (LYG) or quality-adjusted life
years (QALY) gained. Economic results were converted to 2005
Euros. RESULTS: Ten studies were included. Target population,
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